Literature DB >> 21967978

Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia.

Anna Staffas1, Meena Kanduri, Randi Hovland, Richard Rosenquist, Hans Beier Ommen, Jonas Abrahamsson, Erik Forestier, Kirsi Jahnukainen, Ólafur G Jónsson, Bernward Zeller, Josefine Palle, Gudmar Lönnerholm, Henrik Hasle, Lars Palmqvist, Hans Ehrencrona.   

Abstract

Mutation status of FLT3, NPM1, CEBPA, and WT1 genes and gene expression levels of ERG, MN1, BAALC, FLT3, and WT1 have been identified as possible prognostic markers in acute myeloid leukemia (AML). We have performed a thorough prognostic evaluation of these genetic markers in patients with pediatric AML enrolled in the Nordic Society of Pediatric Hematology and Oncology (NOPHO) 1993 or NOPHO 2004 protocols. Mutation status and expression levels were analyzed in 185 and 149 patients, respectively. Presence of FLT3-internal tandem duplication (ITD) was associated with significantly inferior event-free survival (EFS), whereas presence of an NPM1 mutation in the absence of FLT3-ITD correlated with significantly improved EFS. Furthermore, high levels of ERG and BAALC transcripts were associated with inferior EFS. No significant correlation with survival was seen for mutations in CEBPA and WT1 or with gene expression levels of MN1, FLT3, and WT1. In multivariate analysis, the presence of FLT3-ITD and high BAALC expression were identified as independent prognostic markers of inferior EFS. We conclude that analysis of the mutational status of FLT3 and NPM1 at diagnosis is important for prognostic stratification of patients with pediatric AML and that determination of the BAALC gene expression level can add valuable information.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21967978     DOI: 10.1182/blood-2011-05-353185

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

Review 1.  Prognostic significance of FLT3-ITD in pediatric acute myeloid leukemia: a meta-analysis of cohort studies.

Authors:  Xiaoli Wu; Xuefeng Feng; Xiaoqing Zhao; Futian Ma; Na Liu; Hongming Guo; Chaonan Li; Huan Du; Baoxi Zhang
Journal:  Mol Cell Biochem       Date:  2016-07-20       Impact factor: 3.396

2.  High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AML.

Authors:  A Jo; S Mitani; N Shiba; Y Hayashi; Y Hara; H Takahashi; I Tsukimoto; A Tawa; K Horibe; D Tomizawa; T Taga; S Adachi; T Yoshida; H Ichikawa
Journal:  Leukemia       Date:  2015-01-08       Impact factor: 11.528

Review 3.  New approaches for the immunotherapy of acute myeloid leukemia.

Authors:  Terrence L Geiger; Jeffrey E Rubnitz
Journal:  Discov Med       Date:  2015-04       Impact factor: 2.970

4.  Outcome of children with high-risk acute myeloid leukemia given autologous or allogeneic hematopoietic cell transplantation in the aieop AML-2002/01 study.

Authors:  F Locatelli; R Masetti; R Rondelli; M Zecca; F Fagioli; A Rovelli; C Messina; E Lanino; A Bertaina; C Favre; G Giorgiani; M Ripaldi; O Ziino; G Palumbo; M Pillon; A Pession; S Rutella; A Prete
Journal:  Bone Marrow Transplant       Date:  2014-11-10       Impact factor: 5.483

5.  ETS-related gene is a novel prognostic factor in childhood acute lymphoblastic leukemia.

Authors:  Hai-Zhao Zhao; Ming Jia; Ze-Bin Luo; Xiao-Jun Xu; Si-Si Li; Jing-Ying Zhang; Xiao-Ping Guo; Yong-Min Tang
Journal:  Oncol Lett       Date:  2016-11-18       Impact factor: 2.967

Review 6.  Childhood acute myeloid leukaemia.

Authors:  Jeffrey E Rubnitz; Hiroto Inaba
Journal:  Br J Haematol       Date:  2012-09-12       Impact factor: 6.998

7.  Upregulation of Flt3 is a passive event in Hoxa9/Meis1-induced acute myeloid leukemia in mice.

Authors:  A Staffas; L S Arabanian; S Y Wei; A Jansson; S Ståhlman; P Johansson; L Fogelstrand; J Cammenga; F Kuchenbauer; L Palmqvist
Journal:  Oncogene       Date:  2016-09-12       Impact factor: 9.867

8.  Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.

Authors:  Akira Shimada; Yuka Iijima-Yamashita; Akio Tawa; Daisuke Tomizawa; Miho Yamada; Shiba Norio; Tomoyuki Watanabe; Takashi Taga; Shotaro Iwamoto; Kiminori Terui; Hiroshi Moritake; Akitoshi Kinoshita; Hiroyuki Takahashi; Hideki Nakayama; Katsuyoshi Koh; Hiroaki Goto; Yoshiyuki Kosaka; Akiko Moriya Saito; Nobutaka Kiyokawa; Keizo Horibe; Yusuke Hara; Kentaro Oki; Yasuhide Hayashi; Shiro Tanaka; Souichi Adachi
Journal:  Int J Hematol       Date:  2018-01-12       Impact factor: 2.490

Review 9.  Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.

Authors:  Keith J August; Aru Narendran; Kathleen A Neville
Journal:  Drugs       Date:  2013-04       Impact factor: 9.546

Review 10.  How I treat pediatric acute myeloid leukemia.

Authors:  Jeffrey E Rubnitz
Journal:  Blood       Date:  2012-05-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.